Ramirez JL, et al. - Given the link between n-3 polyunsaturated fatty acid (PUFA) supplementation and reduced mortality and inflammation in patients with cardiovascular disease, researchers examined patients with peripheral artery disease (PAD) and for how n-3 PUFA supplementation influences inflammation, endothelial function, and walking ability in them. In the OMEGA-PAD II trial, a double-blinded, randomized, placebo-controlled trial, 24 patients with claudication were randomized to receive 4.4 g/d of fish oil or placebo for 3 months. Patients with PAD who received fish oil showed an increase in specialized pro-resolving lipid mediators (SPMs) in plasma. However, no changes in high-sensitivity C-reactive protein, flow-mediated vasodilation, walking impairment questionnaire, or 6-minute walk test was seen in the fish oil group.